ID   Sup-M2-TS
AC   CVCL_B228
SY   Sup-M2TS; TS
DR   BTO; BTO:0004867
DR   GEO; GSM1217149
DR   Progenetix; CVCL_B228
DR   Wikidata; Q54970879
RX   PubMed=26657151;
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=26657151).
CC   Derived from sampling site: Cerebrospinal fluid.
DI   NCIt; C37193; Anaplastic large cell lymphoma, ALK-positive
DI   ORDO; Orphanet_300895; ALK-positive anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_2209 ! SUP-M2
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 20-05-21; Version: 13
//
RX   PubMed=26657151; DOI=10.1038/onc.2015.456;
RA   Ceccon M., Merlo M.E.B., Mologni L., Poggio T., Varesio L.M.,
RA   Menotti M., Bombelli S., Rigolio R., Manazza A.D., Di Giacomo F.,
RA   Ambrogio C., Giudici G., Casati C., Mastini C., Compagno M.,
RA   Turner S.D., Gambacorti-Passerini C., Chiarle R., Voena C.;
RT   "Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and
RT   drug dependency.";
RL   Oncogene 35:3854-3865(2016).
//